ABSTRACT
Mutations in SCN2A cause epilepsy syndromes of variable severity including neonatal-infantile seizures. In one case, we previously described additional childhood-onset episodic ataxia. Here, we corroborate and detail the latter phenotype in three further cases. We describe the clinical characteristics, identify the causative SCN2A mutations and determine their functional consequences using whole-cell patch-clamping in mammalian cells. In total, four probands presented with neonatal-onset seizures remitting after five to 13 months. In early childhood, they started to experience repeated episodes of ataxia, accompanied in part by headache or back pain lasting minutes to several hours. In two of the new cases, we detected the novel mutation p.Arg1882Gly. While this mutation occurred de novo in both patients, one of them carries an additional known variant on the same SCN2A allele, inherited from the unaffected father (p.Gly1522Ala). Whereas p.Arg1882Gly alone shifted the activation curve by -4 mV, the combination of both variants did not affect activation, but caused a depolarizing shift of voltage-dependent inactivation, and a significant increase in Na(+) current density and protein production. p.Gly1522Ala alone did not change channel gating. The third new proband carries the same de novo SCN2A gain-of-function mutation as our first published case (p.Ala263Val). Our findings broaden the clinical spectrum observed with SCN2A gain-of-function mutations, showing that fairly different biophysical mechanisms can cause a convergent clinical phenotype of neonatal seizures and later onset episodic ataxia.
Subject(s)
Ataxia/genetics , Epilepsy/genetics , Mutation, Missense , NAV1.2 Voltage-Gated Sodium Channel/genetics , Base Sequence , Blotting, Western , DNA Mutational Analysis , Female , Genotype , Humans , Infant, Newborn , Male , Molecular Sequence Data , Mutagenesis, Site-Directed , Patch-Clamp Techniques , Pedigree , Phenotype , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
BACKGROUND: Marinesco-Sjögren syndrome is an autosomal recessive cerebellar ataxia, characterised by cerebellar ataxia, myopathy, cataracts and intellectual disability, due to mutations in the SIL1 gene. METHODS: The clinical features and two novel SIL1 mutations of four Dutch patients with Marinesco-Sjögren syndrome are described and compared to the literature on genetically proven Marinesco-Sjögren patients. RESULTS: The core phenotype of this syndrome appears homogeneous, but: [1] cataract can develop later than the motor and cognitive signs; [2] myopathy is an early feature that seems progressive during the course of the disease; [3] serum creatine kinase is normal or only mildly elevated; [4] peripheral neuropathy is absent; and [5] a variable degree of intellectual disability is present in most Marinesco-Sjögren patients. CONCLUSIONS: Because the late appearance of some hallmarks and the uncertainty as to whether incomplete phenotypes occur, SIL1 mutation analysis is helpful early in the diagnostic work-up of children with suspected inherited ataxias.
Subject(s)
Guanine Nucleotide Exchange Factors/genetics , Mutation , Spinocerebellar Degenerations/complications , Spinocerebellar Degenerations/genetics , Spinocerebellar Degenerations/pathology , Adult , Child , Humans , Male , PhenotypeABSTRACT
OBJECTIVES: To describe clinical characteristics and to identify susceptibility loci for epilepsy and migraine in a Finnish family with a complex phenotype. METHODS: Participating family members were interviewed and medical files were reviewed. The seizure classification was made according to International League Against Epilepsy criteria. Migraine diagnosis was made using the validated Finnish Migraine Specific Questionnaire for Family Studies and criteria according to the current International Classification of Headache Disorders-II. DNA samples were obtained from 56 family members and nonparametric genome-wide linkage analyses were performed using 382 polymorphic microsatellite markers. The most promising loci were fine-mapped with additional microsatellite markers. RESULTS: Clinical data were obtained from 60 family members of whom 12 (20%) had idiopathic epileptic seizures. Eight of those 12 (67%) also had migraine. Altogether 33 of the 60 family members (55%) had migraine. Significant evidence of linkage was found between a locus on 14q12-q23 and migraine (p = 0.0001). Suggestive evidence of linkage in this region was also found for epilepsy with generalized tonic-clonic seizures (p = 0.0034). In addition, significant evidence of linkage was found at a locus on 12q24.2-q24.3 (p < 0.001) for migraine alone and for the combined phenotype of migraine and epilepsy. CONCLUSIONS: Our data suggest the occurrence of common susceptibility loci for epilepsy and migraine on chromosomes 14q12-q23 and 12q24.2-q24.3, implicating a shared genetic etiology for these 2 diseases.
Subject(s)
Chromosomes, Human, Pair 12/genetics , Chromosomes, Human, Pair 14/genetics , Epilepsy/genetics , Genetic Loci/genetics , Linkage Disequilibrium/genetics , Migraine Disorders/genetics , Adolescent , Adult , Child , Female , Finland , Humans , Male , Middle Aged , Pedigree , Young AdultABSTRACT
OBJECTIVE: The idiopathic generalized epilepsies (IGE) are the most common genetically determined epilepsies. However, the underlying genes are largely unknown. We screened the SLC2A1 gene, encoding the glucose transporter type 1 (GLUT1), for mutations in a group of 95 European patients with familial IGE. METHODS: The affected individuals were examined clinically by EEG and brain imaging. The coding regions of SLC2A1 were sequenced in the index cases of all families. Wild-type and mutant transporters were expressed and functionally characterized in Xenopus laevis oocytes. RESULTS: We detected a novel nonsynonymous SLC2A1 mutation (c.694C>T, p.R232C) in one IGE family. Nine family members were affected mainly by absence epilepsies with a variable age at onset, from early childhood to adulthood. Childhood absence epilepsy in one individual evolved into juvenile myoclonic epilepsy. Eight affected and 4 unaffected individuals carried the mutation, revealing a reduced penetrance of 67%. The detected mutation was not found in 846 normal control subjects. Functional analysis revealed a reduced maximum uptake velocity for glucose, whereas the affinity to glucose and the protein expression were not different in wild-type and mutant transporters. CONCLUSION: Our study shows that GLUT1 defects are a rare cause of classic IGE. SLC2A1 screening should be considered in IGE featuring absence epilepsies with onset from early childhood to adult life, because this diagnosis may have important implications for treatment and genetic counseling.
Subject(s)
Epilepsy, Generalized/genetics , Glucose Transporter Type 1/genetics , Mutation , Alleles , Child , Child, Preschool , Female , Genotype , Humans , Male , Neuroimaging , Pedigree , Phenotype , Young AdultABSTRACT
AIMS: CLN8 deficiency underlies one of a group of devastating childhood neurodegenerative disorders, the neuronal ceroid lipofuscinoses. The function of the CLN8 protein is currently unknown, but a role in lipid metabolism has been proposed. In human CLN8 diseased brains, alterations in lipid composition have been detected. To further investigate the connection of CLN8 to lipid metabolism, we characterized the lipid composition of early symptomatic Cln8-deficient mouse (Cln8(mnd)) brains. METHODS: For lipid profiling, Cln8(mnd) cerebral cortical tissue was analysed by liquid chromatography/mass spectrometry. Galactolipid synthesis was measured through enzyme activity and real-time mRNA expression analyses. Based on the findings, myelination and white matter integrity were studied by immunohistochemistry, stereological methods, electron microscopy and magnetic resonance imaging. The development of myelin-forming oligodendrocytes was also studied in vitro. RESULTS: Sphingolipid profiling showed a selective reduction in myelin-enriched galactolipids. The mRNA expression and activity of UDP-galactose:ceramide galactosyltransferase (CGT), the key enzyme in the galactolipid synthesis, was reduced in the Cln8(mnd) brain. Expression of oligodendrocyte markers suggests a maturation defect. The amount of myelin was reduced in 1-month-old Cln8(mnd) mice, but reached normal levels by 5 months of age. The level of Cln8 gene expression followed the developmental pattern of myelin formation and was high in primary oligodendrocytes. CONCLUSIONS: Taken together, these observations suggest that galactolipid deficiency and delayed myelin maturation characterize the early CLN8 disease pathogenesis through a maturation defect of oligodendrocytes.
Subject(s)
Axons , Membrane Proteins/metabolism , Neuronal Ceroid-Lipofuscinoses/metabolism , Oligodendroglia/metabolism , Animals , Axons/metabolism , Axons/ultrastructure , Brain/metabolism , Brain/pathology , Cell Differentiation , Cells, Cultured , Disease Models, Animal , Membrane Proteins/deficiency , Mice , Mice, Knockout , Myelin Sheath/genetics , Myelin Sheath/pathology , Neuronal Ceroid-Lipofuscinoses/genetics , Neuronal Ceroid-Lipofuscinoses/pathology , Oligodendroglia/cytology , Time FactorsABSTRACT
BACKGROUND: Inherited and de novo mutations in sodium channel genes underlie a variety of channelopathies. Mutations in SCN2A, encoding the brain sodium channel Na(V)1.2, have previously been reported to be associated with benign familial neonatal infantile seizures, febrile seizures plus, and intractable epilepsy of infancy. METHODS: We evaluated the clinical characteristics in a patient with a neonatal-onset complex episodic neurologic phenotype. We screened SCN2A for mutations and carried out in vitro electrophysiologic analyses to study the consequences of the identified mutation. We studied the developmental expression of Na(V)1.2 in cerebellum by immunohistochemical analysis. RESULTS: The patient presented with neonatal-onset seizures and variable episodes of ataxia, myoclonia, headache, and back pain after 18 months of age. The patient carries a de novo missense mutation (p.Ala263Val) in SCN2A, which leads to a pronounced gain-of-function, in particular an increased persistent Na(+) current. Immunohistochemical studies suggest a developmentally increasing expression of Na(V)1.2 in granule cell axons projecting to Purkinje neurons. CONCLUSIONS: These results can explain a neuronal hyperexcitability resulting in seizures and other episodic symptoms extending the spectrum of SCN2A-associated phenotypes. The developmentally increasing expression of Na(V)1.2 in cerebellum may be responsible for the later onset of episodic ataxia.
Subject(s)
Ataxia/genetics , Epilepsy/genetics , Mutation/genetics , Myoclonus/genetics , Nerve Tissue Proteins/genetics , Pain/genetics , Sodium Channels/genetics , Age Factors , Animals , Animals, Newborn , Ataxia/complications , Cell Line, Transformed , Cerebellum/growth & development , Cerebellum/metabolism , Cerebellum/pathology , Child , Disease Progression , Electroencephalography/methods , Epilepsy/complications , Gene Expression Regulation, Developmental , Genome-Wide Association Study/methods , Humans , Magnetic Resonance Imaging , Membrane Potentials/genetics , Mice , Myoclonus/complications , NAV1.2 Voltage-Gated Sodium Channel , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Pain/complications , Patch-Clamp Techniques/methods , Sodium Channels/metabolism , Transfection/methods , Video Recording/methodsABSTRACT
Neuronal ceroid lipofuscinoses (NCLs) constitute a group of progressive neurodegenerative disorders resulting from mutations in at least eight different genes. Mutations in the most recently identified NCL gene, MFSD8/CLN7, underlie a variant of late-infantile NCL (vLINCL). The MFSD8/CLN7 gene encodes a polytopic protein with unknown function, which shares homology with ion-coupled membrane transporters. In this study, we confirmed the lysosomal localization of the native CLN7 protein. This localization of CLN7 is not impaired by the presence of pathogenic missense mutations or after genetic ablation of the N-glycans. Expression of chimeric and full-length constructs showed that lysosomal targeting of CLN7 is mainly determined by an N-terminal dileucine motif, which specifically binds to the heterotetrameric adaptor AP-1 in vitro. We also show that CLN7 mRNA is more abundant in neurons than astrocytes and microglia, and that it is expressed throughout rat brain, with increased levels in the granular layer of cerebellum and hippocampal pyramidal cells. Interestingly, this cellular and regional distribution is in good agreement with the autofluorescent lysosomal storage and cell loss patterns found in brains from CLN7-defective patients. Overall, these data highlight lysosomes as the primary site of action for CLN7, and suggest that the pathophysiology underpinning CLN7-associated vLINCL is a cell-autonomous process.
Subject(s)
Membrane Transport Proteins/genetics , Membrane Transport Proteins/metabolism , Neuronal Ceroid-Lipofuscinoses/genetics , Animals , Animals, Newborn , Brain/metabolism , Cells, Cultured , HEK293 Cells , HeLa Cells , Homozygote , Humans , Lysosomes/genetics , Lysosomes/metabolism , Mutation , Neuronal Ceroid-Lipofuscinoses/metabolism , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Transcription Factor AP-1/genetics , Transcription Factor AP-1/metabolism , TransfectionABSTRACT
OBJECTIVE: Mutations in SCARB2 were recently described as causing action myoclonus renal failure syndrome (AMRF). We hypothesized that mutations in SCARB2 might account for unsolved cases of progressive myoclonus epilepsy (PME) without renal impairment, especially those resembling Unverricht-Lundborg disease (ULD). Additionally, we searched for mutations in the PRICKLE1 gene, newly recognized as a cause of PME mimicking ULD. METHODS: We reviewed cases of PME referred for diagnosis over two decades in which a molecular diagnosis had not been reached. Patients were classified according to age of onset, clinical pattern, and associated neurological signs into "ULD-like" and "not ULD-like." After exclusion of mutations in cystatin B (CSTB), DNA was examined for sequence variation in SCARB2 and PRICKLE1. RESULTS: Of 71 cases evaluated, 41 were "ULD-like" and five had SCARB2 mutations. None of 30 "not ULD-like" cases were positive. The five patients with SCARB2 mutations had onset between 14 and 26 years of age, with no evidence of renal failure during 5.5 to 15 years of follow-up; four were followed until death. One living patient had slight proteinuria. A subset of 25 cases were sequenced for PRICKLE1 and no mutations were found. INTERPRETATION: Mutations in SCARB2 are an important cause of hitherto unsolved cases of PME resembling ULD at onset. SCARB2 should be evaluated even in the absence of renal involvement. Onset is in teenage or young adult life. Molecular diagnosis is important for counseling the patient and family, particularly as the prognosis is worse than classical ULD.
Subject(s)
Lysosomal Membrane Proteins/genetics , Mutation , Myoclonic Epilepsies, Progressive/diagnosis , Myoclonic Epilepsies, Progressive/genetics , Receptors, Scavenger/genetics , Renal Insufficiency/genetics , Adolescent , Adult , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Male , Polymerase Chain Reaction , RNA Splicing , Renal Insufficiency/diagnosis , Unverricht-Lundborg Syndrome/diagnosis , Unverricht-Lundborg Syndrome/genetics , Young AdultABSTRACT
OBJECTIVE: To evaluate possible changes in the gray matter volume of patients with Unverricht-Lundborg disease (EPM1) compared with healthy controls. METHODS: Thirty-four genetically verified patients with EPM1 and 30 healthy controls matched for age and sex underwent MRI (T1-, T2-, fluid-attenuated inversion recovery-, and T1-weighted 3-dimensional images). T1-weighted 3-dimensional images were analyzed with voxel-based morphometry (VBM) to compare the regional differences in gray matter volumes between patients and controls. The patients with EPM1 were also clinically evaluated for myoclonus severity using the Unified Myoclonus Rating Scale. RESULTS: VBM analysis revealed atrophy in the bilateral primary, premotor, and supplementary motor cortex. The thalamus and precuneus were also bilaterally affected. No infratentorial changes were detected in the group analysis. CONCLUSION: The cortical motor areas of the brain are particularly affected in EPM1, correlating with the motor symptoms of this disease. The combination of detailed imaging with neurophysiologic evaluation may help to reveal the pathogenesis of Unverricht-Lundborg disease.
Subject(s)
Image Processing, Computer-Assisted/methods , Magnetic Resonance Imaging/methods , Motor Cortex/pathology , Thalamus/pathology , Unverricht-Lundborg Syndrome/pathology , Adolescent , Adult , Atrophy , Female , Humans , Male , Middle Aged , Unverricht-Lundborg Syndrome/genetics , Young AdultABSTRACT
Cohen syndrome is an autosomal recessive disorder that is characterized by mental retardation, facial dysmorphism, microcephaly, retinal dystrophy, truncal obesity, joint laxity and intermittent neutropenia. Mutations in the VPS13B (COH1) gene underlie Cohen syndrome. In approximately 70% of the patients mutations in the gene are identified on both alleles, while in about 30% only a mutation in a single allele or no mutant allele is detected. The VPS13B locus was recently added to the growing list of benign copy number variants. We hypothesized that patients with unexplained Cohen syndrome would harbour deletions affecting the VPS13B locus. We screened 35 patients from 26 families with targeted array CGH and identified 7 copy number alterations: 2 homozygous and 5 heterozygous deletions. Our results show that deletions are an important cause of Cohen syndrome and screening for copy number alterations of VPS13B should be an integral part of the diagnostic work-up of these patients. These findings have important consequences for the diagnosis of patients with genetic disorders in general since, as we highlight, rare benign copy number variants can underly autosomal recessive disorders and lead to disease in homozygous state or in compound heterozygosity with another mutation.
Subject(s)
Abnormalities, Multiple/genetics , Sequence Deletion , Vesicular Transport Proteins/genetics , Abnormalities, Multiple/pathology , Adult , Base Sequence , Child , DNA Mutational Analysis , Humans , Intellectual Disability/genetics , Intellectual Disability/pathology , Male , Microcephaly/genetics , Microcephaly/pathology , Neutropenia/genetics , Neutropenia/pathology , Phenotype , Syndrome , Vesicular Transport Proteins/metabolismABSTRACT
Recent studies have revealed a new type of variation in the human genome encompassing relatively large genomic segments ( approximately 100 kb-2.5 Mb), commonly referred to as copy number variation (CNV). The full nature and extent of CNV and its frequency in different ethnic populations is still largely unknown. In this study we surveyed a set of 12 CNVs previously detected by array-CGH. More than 300 individuals from five different ethnic populations, including three distinct European, one Asian and one African population, were tested for the occurrence of CNV using multiplex ligation-dependent probe amplification (MLPA). Seven of these loci indeed showed CNV, i.e., showed copy numbers that deviated from the population median. More precise estimations of the actual genomic copy numbers for (part of) the NSF gene locus, revealed copy numbers ranging from two to at least seven. Additionally, significant inter-population differences in the distribution of these copy numbers were observed. These data suggest that insight into absolute DNA copy numbers for loci exhibiting CNV is required to determine their potential contribution to normal phenotypic variation and, in addition, disease susceptibility.
Subject(s)
Ethnicity/genetics , Genetic Variation , Base Sequence , Chromosome Mapping , DNA Probes , Genotype , HumansABSTRACT
Mulibrey nanism is a rare autosomal recessive growth disorder with prenatal onset, including occasional progressive cardiopathy, characteristic facial features, failure of sexual maturation, insulin resistance with type 2 diabetes, and an increased risk for Wilms' tumor. Mulibrey nanism is prevalent in the Finnish population and appears extremely rare elsewhere. However, cases outside of Finland may be underdiagnosed or misdiagnosed as having the 3-M or Silver-Russell syndrome, two important differential diagnostic disorders. Here, we report the first Australian patient with mulibrey nanism, in whom the occurrence of Wilms' tumor suggested the correct diagnosis. This was confirmed by the identification of two novel mutations in tripartite motif protein 37 (TRIM37) encoding a RING finger ubiquitin E3 ligase. Both mutations, the p.Cys109Ser B-box missense mutation and the p.Glu271_Ser287del in-frame deletion in the tumor necrosis factor receptor associated factor (TRAF) domain alter the subcellular localization of TRIM37. As both the B-box and the TRAF domains are predicted to be important for mediating the protein-protein interactions, these mutations may help the understanding of the cellular interactions of TRIM37. Our findings imply the importance of early molecular diagnostics in cases of suspected mulibrey nanism and of identifying novel mutations with potential relevance for unraveling the underlying molecular pathology. Ultrasound surveillance for Wilms' tumor is recommended for children with mulibrey nanism.
Subject(s)
Kidney Neoplasms/genetics , Mulibrey Nanism/genetics , Mutation/genetics , Nuclear Proteins/genetics , Wilms Tumor/genetics , Australia , Base Sequence , DNA Mutational Analysis , DNA Primers , Female , Fluorescent Antibody Technique , Humans , Infant , Reverse Transcriptase Polymerase Chain Reaction , Tripartite Motif Proteins , Ubiquitin-Protein Ligases , White PeopleABSTRACT
Neuronal ceroid lipofuscinoses (NCLs) are the most common neurodegenerative childhood-onset disorders characterized by autosomal recessive inheritance, epileptic seizures, progressive psychomotor deterioration, visual failure, and premature death. At least seven subtypes of childhood-onset NCLs have been identified of which the late-infantile-onset forms (LINCLs) are genetically the most heterogeneous with four underlying genes identified. A variant form of LINCL (vLINCL) present in Turkish patients has been considered a distinct clinical and genetic entity (CLN7). However, we recently showed that mutations in the CLN8 gene account for a subset of Turkish vLINCL. Toward identifying the CLN7 gene we here screened the known NCL loci for homozygosity in nine Turkish vLINCL families. These loci were excluded in seven families that are likely to represent the 'true' Turkish vLINCL. In two families, we identified two novel homozygous mutations in the CLN6 gene: an intronic base substitution (c.542+5G>T) affecting the splicing of the transcript and a nonsense mutation (c.663C>G) creating a stop codon at tyrosine 221. These data indicate that CLN6 mutations, in addition to those of CLN8, should be considered a diagnostic alternative in Turkish vLINCL patients. The genetic background of the 'true' Turkish vLINCL, CLN7, remains to be defined.
Subject(s)
Membrane Proteins/genetics , Neuronal Ceroid-Lipofuscinoses/ethnology , Neuronal Ceroid-Lipofuscinoses/genetics , Age of Onset , Child, Preschool , DNA Mutational Analysis , Female , Haplotypes , Humans , Male , Pedigree , Point Mutation , Turkey/ethnologySubject(s)
Abnormalities, Multiple/genetics , Abnormalities, Multiple/physiopathology , Brain/abnormalities , Eye Abnormalities/genetics , Muscular Dystrophies/genetics , Mutation/genetics , N-Acetylglucosaminyltransferases/genetics , Abnormalities, Multiple/pathology , Adolescent , Adult , Brain/physiopathology , Child , Child, Preschool , DNA Mutational Analysis , Exons/genetics , Eye Abnormalities/physiopathology , Female , Finland , Founder Effect , Haplotypes/genetics , Humans , Infant , Infant, Newborn , Introns/genetics , Male , Muscular Dystrophies/congenital , Muscular Dystrophies/physiopathology , Phenotype , Polymorphism, Single Nucleotide/geneticsSubject(s)
ATP-Binding Cassette Transporters/genetics , Cholestasis, Intrahepatic/genetics , Exons/genetics , Polymorphism, Single Nucleotide/genetics , Pregnancy Complications/etiology , ATP Binding Cassette Transporter, Subfamily B, Member 11 , Case-Control Studies , Female , Finland , Humans , Male , PregnancyABSTRACT
BACKGROUND AND AIMS: The aim of this study was to investigate the genetic aetiology of intrahepatic cholestasis of pregnancy (ICP) and the impact of known cholestasis genes (BSEP, FIC1, and MDR3) on the development of this disease. PATIENTS AND METHODS: Sixty nine Finnish ICP patients were prospectively interviewed for a family history of ICP, and clinical features were compared in patients with familial ICP (patients with a positive family history, n=11) and sporadic patients (patients with no known family history of ICP, n=58). For molecular genetic analysis, 16 individuals from two independently ascertained Finnish ICP families were genotyped for the flanking markers for BSEP, FIC1, and MDR3. RESULTS: The pedigree structures in 16% (11/69) of patients suggested dominant inheritance. Patients with familial ICP had higher serum aminotransferase levels and a higher recurrence risk (92% v 40%). Both segregation of haplotypes and multipoint linkage analysis excluded BSEP, FIC1, and MDR3 genes in the studied pedigrees. Additionally, the MDR3 gene, previously shown to harbour mutations in ICP patients, was negative for mutations when sequenced in four affected individuals from the two families. CONCLUSIONS: These results support the hypothesis that the aetiology of ICP is heterogeneous and that ICP is due to a genetic predisposition in a proportion of patients. The results of molecular genetic analysis further suggest that the previously identified three cholestasis genes are not likely to be implicated in these Finnish ICP families with dominant inheritance.
Subject(s)
Cholestasis, Intrahepatic/genetics , Genetic Heterogeneity , Pregnancy Complications/etiology , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP-Binding Cassette Transporters/genetics , Adult , Bile Acids and Salts/blood , Cholestasis, Intrahepatic/epidemiology , Family Health , Female , Finland/epidemiology , Genes, Dominant/genetics , Genetic Linkage/genetics , Genotype , Haplotypes/genetics , Humans , Incidence , Pedigree , Pregnancy , Pregnancy Complications/epidemiology , Prospective Studies , Transaminases/bloodABSTRACT
Cohen syndrome is a rare, recessively inherited condition associated with facial dysmorphism, developmental delay, and visual disability. A delay in making the diagnosis commonly occurs, contributed to by the lack of a definitive molecular test and the clinical variability of published case reports. A specific clinical phenotype has been delineated in a homogeneous cohort of Finnish Cohen syndrome patients, but the applicability of their diagnostic criteria to non-Finnish patients has been debated. Detailed delineation of Cohen syndrome in patients from outside Finland is therefore warranted. We report on the clinical features of 33 non-Finnish Cohen syndrome patients. Variability within the clinical spectrum is identified and the natural history of Cohen syndrome described. Diagnostic guidelines for facilitating accurate and early diagnosis are discussed. Results from molecular genetic analysis using markers located within the previously mapped COH1 critical region support allelic but not genetic heterogeneity in this UK cohort.
Subject(s)
Abnormalities, Multiple/pathology , Developmental Disabilities/pathology , Face/abnormalities , Learning Disabilities/pathology , Abnormalities, Multiple/diagnosis , Abnormalities, Multiple/genetics , Adolescent , Adult , Child , Child, Preschool , Chromosomes, Human, Pair 8/genetics , Cohort Studies , Diagnosis, Differential , Eye Diseases/pathology , Family Health , Female , Haplotypes , Humans , Infant , Limb Deformities, Congenital/pathology , Male , Microsatellite Repeats , Middle Aged , Pedigree , SyndromeSubject(s)
Anticonvulsants/therapeutic use , Myoclonic Epilepsies, Progressive/drug therapy , Piracetam/analogs & derivatives , Piracetam/therapeutic use , Adult , Amino Acid Substitution , Chromosomes, Human, Pair 21/genetics , Cystatin B , Cystatins/genetics , Drug Evaluation , Female , Heterozygote , Humans , Levetiracetam , Minisatellite Repeats , Mutation, Missense , Myoclonic Epilepsies, Progressive/genetics , Point Mutation , Promoter Regions, Genetic/geneticsABSTRACT
MRI of the brain and proton MRS ((1)H MRS) of the pons and dentate were obtained in 10 patients with genetically confirmed Unverricht-Lundborg disease (EPM1) and 20 control subjects. Patients with EPM1 showed (p < or = 0.01) loss of bulk of the basis pontis, medulla, and cerebellar hemispheres. Cerebral atrophy was present in six patients. The N-acetylaspartate/creatine and choline/creatine ratios were reduced in the pons but not in the dentate (p < or = 0.005). Brainstem involvement could play a role in pathophysiology of EPM1.